💡 Great insights from the 14th Annual Meeting of the French Society of Radiopharmacy (Société Française de Radiopharmacie SoFRa) last Friday.

Nicolas Mario, our Head of Market & Supply at MEDraysintell, contributes to an expert roundtable focused on Targeted Radionuclide Therapy (TRNT) and its growing impact in nuclear medicine, moderated by Philippe Garrigue (APHM (Assistance Publique – Hopitaux de Marseille), with Arnaud Lesegretain (Orano Med), Juliette FEUARDENT (ASNR – Autorité de sûreté nucléaire et de radioprotection), Cécile Bourdeau (GIP ARRONAX) and Dr. Mickaël Bourgeois (CHU de Nantes).

As a leading market intelligence partner in nuclear medicine, MEDraysintell supports industry players, investors and policymakers with strategic insights to drive innovation and ensure long-term sustainability.

Key takeaways from this discussion:
➡️ The need to build sustainable and reliable European production capacity for radionuclides and radiopharmaceuticals, especially to support clinical trials,
➡️ The importance of streamlined regulatory frameworks, developed hand-in-hand between competent authorities and clinical stakeholders,
➡️ The benefits from accelerating patient access to promising and innovative treatments,
➡️ The investment dynamics and clinical research interest around next-generation radiopharmaceutical therapies.

Let’s continue shaping the future of nuclear medicine together!